지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 284 - 291 (8page)
이용수
초록· 키워드
오류제보하기
Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261). Materials and Methods Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). Results In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%). Conclusion Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Tan DS / 2016 / The International Association for the Study of Lung Cancer Consensus Statement on optimizing management of EGFR mutation-positive non-small cell lung cancer : status in 2016 / J Thorac Oncol 11:946~963
Hanna N / 2017 / Systemic therapy for stage IV non-small-cell lung cancer : American Society of Clinical Oncology Clinical Practice Guideline update / J Clin Oncol 35:3484~3515
Planchard D / 2018 / Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Ann Oncol 29(Suppl 4):iv192~iv237
Rosell R / 2012 / Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial / Lancet Oncol 13:239~246
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
Hanna N / 2017 / Systemic therapy for stage IV non-small-cell lung cancer : American Society of Clinical Oncology Clinical Practice Guideline update / J Clin Oncol 35:3484~3515
Planchard D / 2018 / Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Ann Oncol 29(Suppl 4):iv192~iv237
Rosell R / 2012 / Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial / Lancet Oncol 13:239~246
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .01
-
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Cancer Research and Treatment
2022 .10
-
Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
Cancer Research and Treatment
2018 .01
-
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Cancer Research and Treatment
2019 .01
-
비소세포폐암 환자의 표적 치료
대한내과학회지
2024 .04
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
Yonsei Medical Journal
2019 .01
-
Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?
예방의학회지
2019 .01
-
비소세포폐암에서 완전절제술 후 보조항암요법
대한의사협회지
2023 .03
-
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cancer Research and Treatment
2019 .01
-
Profile Analysis of Sexual Assault Experiences among Adult Women and Their Implications for Mental Health
PSYCHIATRY INVESTIGATION
2021 .01
-
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Prognostic Value of Estrogen and Progesterone Receptor Expression in Low Proliferative Human Epidermal Growth Factor Receptor 2- Negative Breast Cancer
Journal of Breast Disease
2017 .12
-
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Cancer Research and Treatment
2023 .01
-
비소세포폐암 줄기세포에서 로즈마린산의 항증식 효과
생약학회지(Korean Journal of Pharmacognosy)
2024 .09
-
Immunotherapy for Non-small-cell Lung Cancer : Current Status and Future Obstacles
Immune Network
2017 .12
-
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment
Cancer Research and Treatment
2019 .01
-
Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
Annals of Laboratory Medicine
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0